Trial Profile
Phase II study of zoledronic acid concomitant with androgen deprivation therapy for patients with treatment-naive bone-metastatic prostate cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Jun 2016
Price :
$35
*
At a glance
- Drugs Bicalutamide (Primary) ; Goserelin (Primary) ; Zoledronic acid (Primary)
- Indications Bone metastases; Prostate cancer
- Focus Therapeutic Use
- 06 Mar 2013 Status changed from active, no longer recruiting to completed as reported by University Hospital Medical Information Network - Japan.
- 26 Mar 2012 New trial record